A citation-based method for searching scientific literature

John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
Times Cited: 92







List of co-cited articles
1316 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Orville G Kolterman, John B Buse, Mark S Fineman, Eling Gaines, Sonja Heintz, Thomas A Bicsak, Kristin Taylor, Dennis Kim, Maria Aisporna, Yan Wang,[...]. J Clin Endocrinol Metab 2003
421
27


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
934
20


The role of adjunctive exenatide therapy in pediatric type 1 diabetes.
Vandana S Raman, Kimberly J Mason, Luisa M Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A Heptulla. Diabetes Care 2010
60
30

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
C M Edwards, S A Stanley, R Davis, A E Brynes, G S Frost, L J Seal, M A Ghatei, S R Bloom. Am J Physiol Endocrinol Metab 2001
350
18

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.
Margaret T Behme, John Dupré, Thomas J McDonald. BMC Endocr Disord 2003
53
32

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
J Dupre, M T Behme, I M Hramiak, P McFarlane, M P Williamson, P Zabel, T J McDonald. Diabetes 1995
120
18

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
18



Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
Mark S Fineman, Thomas A Bicsak, Larry Z Shen, Kristin Taylor, Eling Gaines, Amanda Varns, Dennis Kim, Alain D Baron. Diabetes Care 2003
264
17

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
17

Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
16


Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Michael A Nauck, Markus M Heimesaat, Kai Behle, Jens J Holst, Markus S Nauck, Robert Ritzel, Michael Hüfner, Wolff H Schmiegel. J Clin Endocrinol Metab 2002
398
15


A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
14

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
906
14


One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Kristine B Degn, Claus B Juhl, Jeppe Sturis, Grethe Jakobsen, Birgitte Brock, Visvanathan Chandramouli, Joergen Rungby, Bernard R Landau, Ole Schmitz. Diabetes 2004
330
14

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.
M Szayna, M E Doyle, J A Betkey, H W Holloway, R G Spencer, N H Greig, J M Egan. Endocrinology 2000
239
14

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Orville G Kolterman, Dennis D Kim, Larry Shen, James A Ruggles, Loretta L Nielsen, Mark S Fineman, Alain D Baron. Am J Health Syst Pharm 2005
296
14



Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
D G Parkes, R Pittner, C Jodka, P Smith, A Young. Metabolism 2001
210
14

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
897
14

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
14


Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
N H Greig, H W Holloway, K A De Ore, D Jani, Y Wang, J Zhou, M J Garant, J M Egan. Diabetologia 1999
180
13

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
476
13

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
Bo Ahrén, Mona Landin-Olsson, Per-Anders Jansson, Maria Svensson, David Holmes, Anja Schweizer. J Clin Endocrinol Metab 2004
516
13

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
Loredana Farilla, Angela Bulotta, Boaz Hirshberg, Sergio Li Calzi, Nasif Khoury, Houtan Noushmehr, Cristina Bertolotto, Umberto Di Mario, David M Harlan, Riccardo Perfetti. Endocrinology 2003
464
13


Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
M B Toft-Nielsen, M B Damholt, S Madsbad, L M Hilsted, T E Hughes, B K Michelsen, J J Holst. J Clin Endocrinol Metab 2001
610
13

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
13

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
13


Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
11

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
658
11

Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.
P Shah, A Vella, A Basu, R Basu, W F Schwenk, R A Rizza. J Clin Endocrinol Metab 2000
294
11

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Robert J Heine, Luc F Van Gaal, Don Johns, Michael J Mihm, Mario H Widel, Robert G Brodows. Ann Intern Med 2005
598
11



Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
Bo Ahrén, Ramon Gomis, Eberhard Standl, David Mills, Anja Schweizer. Diabetes Care 2004
375
10


Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
637
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.